This invention relates generally to methods and pharmaceutical formulations useful in treating patients suffering from sleep apnea, including obstructive sleep apnea syndrome (OSAS). Treatment is effected by administering a carbonic anhydrase inhibitor to the patient in combination with an aldosterone antagonist. Formulations containing a therapeutically effective amount of a carbonic anhydrase inhibitor and a therapeutically effective amount of an aldosterone antagonist are provided as well.

Download PDF
Document Preview
Document History
  • Publication: Feb 18, 2016
  • Application: Aug 13, 2015
    WO US 2015/0044978 W
  • Priority: Aug 14, 2014
    US US 201462037244 P

Sign in to the Lens